ExploreWatchlistsPricing
  1. JP-listed companies
  2. Immuno-Biological Laboratories Co., Ltd.
  3. Financials
  4. Revenue growth (%)

Immuno-Biological Laboratories Co., Ltd. (4570)

Market cap
¥14.1B
P/E ratio
53.1x
Develops antibody-based diagnostic tools and testing services for medical research, plus manufactures cosmetics using human-type collagen from silkworms.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndRevenue growth (%) YoY (%)
Mar 31, 202518.7+573.02%
Mar 31, 20242.8-87.76%
Mar 31, 202322.7+205.24%
Mar 31, 20227.4+64.60%
Mar 31, 20214.5-117.27%
Mar 31, 2020-26.2-966.89%
Mar 31, 20193+33.63%
Mar 31, 20182.3-32.13%
Mar 31, 20173.3-313.46%
Mar 31, 2016-1.6-117.85%
Mar 31, 20158.7-153.95%
Mar 31, 2014-16.2+28.67%
Mar 31, 2013-12.6

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat